Latest revenue
$73.7M
as of 2026-03-31
Latest net income
$-101.9M
as of 2026-03-31
Net margin
-138.2%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $10.56B
- Enterprise value
- $10.56B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $82.26
- 52-wk low
- $14.30
- Beta
- —
- Shares out
- 140.9M
5-year trend
What this company does
ITEM 1.BUSINESS A.Overview The Company develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. There are currently 18 Arrowhead discovered drug candidates in clinical trials ranging from early stage (Phase 1) to late stage (Phase 3). In addition, the company has a robust discovery stage pipeline which is capable of generating multiple new clinical candidates each year. The Company recently achieved a transformational milestone with its first commercial launch in 2025,…
AI summary unavailable — showing raw filing excerpt
Generated from ARWR's filing dated 2025-11-25
Key risks
ITEM 1A.RISK FACTORS The Company’s business involves various risks and uncertainties in addition to the normal risks of business, some of which are discussed in this section. It should be noted that the Company’s business may be adversely affected by general economic conditions and other factors beyond the Company’s control. In addition, other risks and uncertainties not presently known or that the Company currently believes to be immaterial may also adversely affect the Company’s business. Some of the factors, events, and contingencies discussed below may have occurred in the past, but the disclosures below are not representations as to whether or not the factors, events, or contingencies…
AI summary unavailable — showing raw filing excerpt
Generated from ARWR's filing dated 2025-11-25
Profitability
Operating margin
11.9%
100.1%Net margin
-0.2%
100.0%Return on equity
-0.3%
99.9%Return on assets
-0.1%
99.8%Leverage
Debt / equity
1.97×
61.7%Long-term debt / equity
0.46×
78.3%Debt / assets
66.4%
20.7%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $73.7M | -86.4% | $-101.9M | -151.6% | -138.2% |
Q4 2025 2025-12-31 | $264.0M | +10461.3% | $30.8M | +117.8% | 11.7% |
Q3 2025 2025-09-30 | $256.5M | — | $-48.0M | +71.8% | -18.7% |
Q2 2025 2025-06-30 | $27.8M | — | $22.1M | +113.0% | 79.7% |
Q1 2025 2025-03-31 | $542.7M | — | $197.4M | +257.5% | 36.4% |
Q4 2024 2024-12-31 | $2.5M | -29.6% | $-173.1M | -30.3% | -6923.4% |
Q3 2024 2024-09-30 | $0 | — | $-170.5M | — | — |
Q2 2024 2024-06-30 | $0 | -100.0% | $-170.8M | -78.7% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ARWR — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$37.9M
Net activity
−$37.9M
Distinct insiders
10
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ARWR
Institutional value
$3.47B
Total shares held
56.0M
Distinct holders
266
-132 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 18.2M | $1.14B | -3.2M (-14.8%) | Trimmed |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 7.1M | $448.1M | — | New |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 6.0M | $378.2M | — | New |
| 4 | Invesco Ltd. | 3.3M | $205.7M | +2.7M (+498.9%) | Added |
| 5 | UBS Group AG | 1.3M | $83.8M | +349.0K (+35.3%) | Added |
| 6 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1.3M | $83.5M | +70.6K (+5.6%) | Added |
| 7 | Pictet Asset Management Holding SA | 1.3M | $79.6M | +244.5K (+23.8%) | Added |
| 8 | Fisher Asset Management, LLC | 1.1M | $69.8M | -198.2K (-15.1%) | Trimmed |
| 9 | VANGUARD FIDUCIARY TRUST CO | 965.8K | $60.6M | — | New |
| 10 | Bank of New York Mellon Corp | 960.1K | $60.2M | +72.3K (+8.1%) | Added |
| 11 | Connor, Clark & Lunn Investment Management Ltd. | 837.0K | $52.5M | +173.7K (+26.2%) | Added |
| 12 | Western Financial Corp/CA | 820.2K | $51.4M | +0 (+0.0%) | No change |
| 13 | Voya Investment Management LLC | 656.1K | $41.1M | +233.4K (+55.2%) | Added |
| 14 | BNP PARIBAS FINANCIAL MARKETS | 650.6K | $40.8M | +610.2K (+1510.5%) | Added |
| 15 | JPMORGAN CHASE & CO | 683.1K | $39.4M | +71.2K (+11.6%) | Added |
| 16 | DIMENSIONAL FUND ADVISORS LP | 608.5K | $38.1M | +461.1K (+312.8%) | Added |
| 17 | Nuveen, LLC | 499.8K | $31.3M | +211.3K (+73.2%) | Added |
| 18 | PRINCIPAL FINANCIAL GROUP INC | 490.1K | $30.7M | -225.4K (-31.5%) | Trimmed |
| 19 | FRANKLIN RESOURCES INC | 462.7K | $29.0M | +355.3K (+331.0%) | Added |
| 20 | RHUMBLINE ADVISERS | 404.4K | $25.4M | +52.0K (+14.8%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ARWR's latest filing finishes processing.